Efficacy of Pgp3 vaccination for urogenital tract infection depends on its native conformation.

Urogenital tract infections with have frequently been detected among patients diagnosed with sexually transmitted infections, and such infections lead to inflammatory complications. Currently, no licensed chlamydial vaccine is available in clinical practice. We previously reported that immunization with recombinant plasmid-encoded virulence factor Pgp3 provided cross-serovar protection against genital tract infection.